Growth in U.S. healthcare spending slowed in 2017

National health spending grew by 3.9 percent in 2017, about 1 percent slower growth than the previous year, according to the Office of the Actuary at CMS. Total healthcare spending reached $3.5 trillion in 2017, or $10,739 per person.

The overall growth in spending was below the 4.2 percent growth of the overall economy in 2017, and healthcare spending made up 18 percent of the economy.

Medicare spending grew at about the same rate from 2016 to 2017, around 4.2 percent, but Medicaid spending growth slowed to 2.9 percent in 2017, compared to 4.2 percent in 2016.

Slower spending growth was led by hospital spending, which makes up 33 percent of total spending, physician and clinical services spending (20 percent of total spending), and retail prescription drug spending (10 percent of total spending).

Hospital spending dropped from 5.6 percent growth in 2016 to 4.6 percent in 2017, according to the data. This change was driven by slower growth in the use and intensity of services. Physician and clinical services spending grew 4.2 percent to $694.3 billion in 2017, down from 5.6 percent growth in 2016 and 6 percent in 2015.

Retail prescription drug spending increased by just 0.4 percent in 2017, to $333.4 billion. The drop in spending growth was significant, compared to 2.3 percent growth in 2016, 8.9 percent in 2015 and 12.4 percent in 2014.

“Retail prescription drug spending growth slowed in 2017 primarily due to slower growth in the number of prescriptions dispensed, a continued shift to lower-cost generic drugs, slower growth in the volume of some high-cost drugs, declines in generic drug prices, and lower price increases for existing brand-name drugs,” according to the Office of the Actuary.

See all the numbers here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.